AR044371A1 - Derivados de 6,7 dimetoxi isoquinolinas, inhibidores de gfta, compuestos, procedimiento, composicion farmaceutica y usos - Google Patents

Derivados de 6,7 dimetoxi isoquinolinas, inhibidores de gfta, compuestos, procedimiento, composicion farmaceutica y usos

Info

Publication number
AR044371A1
AR044371A1 ARP040101698A ARP040101698A AR044371A1 AR 044371 A1 AR044371 A1 AR 044371A1 AR P040101698 A ARP040101698 A AR P040101698A AR P040101698 A ARP040101698 A AR P040101698A AR 044371 A1 AR044371 A1 AR 044371A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
heterocyclic ring
heteroatoms
alkoxide
Prior art date
Application number
ARP040101698A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR044371A1 publication Critical patent/AR044371A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Los compuestos tienen utilidad para el tratamiento de la diabetes tipo II. Reivindicación 1: Compuestos de fórmula (1), donde: R1 es -alquilo inferior, -CH2-arilo, -cicloalquilo, -(CH2)3 -OC(=O)CH3, -alcohol inferior, -alquilo inferior-R10, - CH2COOH, o -CH2CH2OCH2CH3; R2 es -alquilo inferior, -CH2-arilo, -alcohol inferior, -CH2C(=O)NH2, o -alquilo inferior-R10, donde al menos uno de R1 o R2 es -CH3; R3 es -COOH, -alquilo inferior-COOH, -alcohol inferior, -CH2OCH3, -CH2NH2, -CH2NHSO2R11, -C(=O)R12, -CNHCH2CH2-R12, -C(=NH)-R12, -(CH2)nNHC(=O)R13, -(CH2)mC(=O)N(R15)(R16), -C(=NH)-R17, o -(CH2)n-R18; R4 es -H, -alcóxido inferior, -O-C(R7R8)C(=O)R19, -halógeno, -SCH3, -C=CHC(=O)-R10, -CH2CH2C(=O)-R10, -O-alcohol inferior, - OCH2CH(OH)CH2N=N+=N-, -OCH2CH2OCH2CH2Cl, -NHC(=O)CH2-R10, -NHC(=O)CH2-alquilo inferior, -O(CH2)n-cicloalquilo, -O-alqueno inferior, o un anillo heterocíclico insaturado de 5 miembros que contiene un heteroátomo que es S o O; R5 y R6 son cada uno independientemente -H, -halógeno o -alcóxido inferior; R7 y R8 son cada uno independientemente -H o -CH3; R10 es un heterociclilo saturado de 5 ó 6 miembros que contiene 1 ó 2 heteroátomos, donde cada heteroátomo se selecciona entre N y O y el grupo se une al resto de la molécula a un N del anillo; R11 es -CF3, -alquilo inferior, -CH2Cl, -CH2CF3, o -R12; R12 es un anillo heterocíclico de 5 ó 6 miembros saturado sustituido o no sustituido que contiene un heteroátomo que se selecciona entre N, O y S donde el anillo sustituido es el anillo heterocíclico sustituido con -OH o -fenilo; R13 es -alquilo inferior, -alcóxido inferior, o -(CH2)nR14; R14 es un anillo heterocíclico de 5 ó 6 miembros saturado o insaturado que contiene uno o dos heteroátomos que son seleccionados entre N y O; R15 es -H o -CH3; R16 es -H, -alquilo inferior, -CºN, -OH, -alcóxido inferior, o -CH2COOCH2CH3; R17 es -alcóxido inferior -NH2 o -N-alquilo inferior; R18 es un anillo heterocíclico saturado o insaturado de 5 miembros sustituido o no sustituido que contiene de 1 a 4 heteroátomos donde los heteroátomos se seleccionan entre N, O y S, donde el anillo sustituido es el anillo heterocíclico que está sustituido en uno o dos carbonos del anillo con =O, o sustituido en un N del anillo con -alcohol inferior o -alquilo inferior; R19 es -OH, -NHCH(CH3)2, -N(CH3)CH2-arilo, -N(CH3)-alquilo inferior, o la fórmula (2), o un heterociclilo de 5 ó 6 miembros saturado sustituido o no sustituido que contiene 1 ó 2 heteroátomos donde cada heteroátomo es independientemente seleccionado entre N, O y S, donde dicho heterociclilo sustituido es el heterociclilo sustituido con alquilo inferior; m es 0, 1 ó 2; n es 0 ó 1; y sus sales y ésteres farmacéuticamente aceptables.
ARP040101698A 2003-05-19 2004-05-17 Derivados de 6,7 dimetoxi isoquinolinas, inhibidores de gfta, compuestos, procedimiento, composicion farmaceutica y usos AR044371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47169003P 2003-05-19 2003-05-19

Publications (1)

Publication Number Publication Date
AR044371A1 true AR044371A1 (es) 2005-09-07

Family

ID=33452454

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101698A AR044371A1 (es) 2003-05-19 2004-05-17 Derivados de 6,7 dimetoxi isoquinolinas, inhibidores de gfta, compuestos, procedimiento, composicion farmaceutica y usos

Country Status (19)

Country Link
US (1) US7067529B2 (es)
EP (1) EP1631551A2 (es)
JP (1) JP2006528218A (es)
KR (1) KR100785571B1 (es)
CN (1) CN100540537C (es)
AR (1) AR044371A1 (es)
AU (1) AU2004238521B2 (es)
BR (1) BRPI0410760A (es)
CA (1) CA2524958A1 (es)
CL (1) CL2004001069A1 (es)
CO (1) CO5630035A2 (es)
MX (1) MXPA05012415A (es)
MY (1) MY142768A (es)
NO (1) NO20054852L (es)
NZ (1) NZ543065A (es)
RU (1) RU2320648C2 (es)
TW (1) TW200426144A (es)
WO (1) WO2004101528A2 (es)
ZA (1) ZA200509290B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8524444B2 (en) 2007-06-15 2013-09-03 President And Fellows Of Harvard College Methods and compositions for detections and modulating O-glycosylation
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
WO2009107072A1 (en) * 2008-02-29 2009-09-03 The Procter & Gamble Company Hair care compositions and methods for increasing hair diameter
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
BRPI0923592A2 (pt) * 2008-12-25 2016-01-26 Taisho Pharmaceutical Co Ltd composto
JP2012528858A (ja) 2009-06-01 2012-11-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ Ｏ−ＧｌｃＮＡｃ転移酵素阻害剤およびその使用
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2586772A4 (en) * 2010-06-23 2013-11-13 Taisho Pharmaceutical Co Ltd isoquinoline
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2013006758A1 (en) 2011-07-06 2013-01-10 President And Fellows Of Harvard College Diphosphate mimetics and uses thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105188850A (zh) 2013-05-16 2015-12-23 宝洁公司 毛发增稠组合物及使用方法
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
WO2020047251A1 (en) 2018-08-29 2020-03-05 President And Fellows Of Harvard College O-glcnac transferase inhibitors and uses thereof
CN109456268A (zh) * 2018-11-08 2019-03-12 中国药科大学 C1位取代的3，4－二氢异喹啉类生物碱的制备及其医药用途
CN110642854A (zh) * 2019-11-20 2020-01-03 成都克莱蒙医药科技有限公司 一种稠环化合物的多晶型、其组合物、制备方法及其应用
TW202214585A (zh) * 2020-06-08 2022-04-16 加拿大商愛彼特生物製藥公司 經取代之異喹啉基甲基醯胺類、其類似物及使用其之方法
WO2022150962A1 (en) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2199462A1 (en) 1972-09-21 1974-04-12 Bruneau & Cie Lab Papaveraldime oxime ethers and esters - analgesics and antiinflammatories prepd by treatment of papaveraldime oxime with an alkyl or acyl halide
GB1407685A (en) * 1972-10-19 1975-09-24 Allen & Hanburys Ltd Isoquinolinium compounds
US4042697A (en) 1972-10-19 1977-08-16 Allen & Hanburys Limited Isoquinolium compounds for treating diabetes
JPS63310813A (ja) 1987-06-12 1988-12-19 Keikichi Sugiyama 毛髪用組成物
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
US6400710B1 (en) * 1999-07-09 2002-06-04 Enron Warspeed Services, Inc. Network with hot button for providing switched broadband multipoint/multimedia intercommunication
ES2172376B1 (es) 2000-01-28 2003-11-16 Servier Lab Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Also Published As

Publication number Publication date
ZA200509290B (en) 2007-04-25
CN1791581A (zh) 2006-06-21
CA2524958A1 (en) 2004-11-25
BRPI0410760A (pt) 2006-06-27
US7067529B2 (en) 2006-06-27
CN100540537C (zh) 2009-09-16
JP2006528218A (ja) 2006-12-14
NO20054852L (no) 2005-12-13
MXPA05012415A (es) 2006-02-13
EP1631551A2 (en) 2006-03-08
KR100785571B1 (ko) 2007-12-13
NZ543065A (en) 2009-07-31
US20040259910A1 (en) 2004-12-23
WO2004101528A3 (en) 2005-01-06
RU2320648C2 (ru) 2008-03-27
WO2004101528A2 (en) 2004-11-25
RU2005139524A (ru) 2007-06-27
KR20060015267A (ko) 2006-02-16
NO20054852D0 (no) 2005-10-20
TW200426144A (en) 2004-12-01
AU2004238521B2 (en) 2007-07-26
CO5630035A2 (es) 2006-04-28
AU2004238521A1 (en) 2004-11-25
MY142768A (en) 2010-12-31
HK1091838A1 (zh) 2007-01-26
CL2004001069A1 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
CO5630035A2 (es) Inhibidores de gfat
AR030432A1 (es) Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.
AR036114A1 (es) Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20020855A1 (es) Derivados de piperazina azaindoloxoacetico sustituidos con actividad antiviral
AR070811A1 (es) Derivados de 1- bencil-3- hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40
AR113918A1 (es) Agentes antivirales contra la hepatitis b
UY27357A1 (es) Nuevos agentes antidiabéticos .
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
MA50065B1 (fr) Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53
PE20000932A1 (es) Nuevos derivados sustituidos de pirazol
AR061422A2 (es) Peptidos ciclicos selectivos, procedimiento de preparacion, composicion farmaceutica que los comprende, y uso de los mismos en la preparacion de medicamentos
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
PE20010152A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
PE20010637A1 (es) Derivados del acido aminodicarboxilico como estimulantes de la guanilato ciclasa
RU2011106374A (ru) Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
PE73299A1 (es) Derivados de nicotinamida
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
AR003947A1 (es) Utilizacion de una cantidad efectiva de como minimo un compuesto de tipo retinoide como agente activo en una composicion cosmetica o para la fabricacionde una composicion farmaceutica, y compuestos especificos de dicho tipo.
DE50303835D1 (de) Haarbehandlungsmittel und Haarnachbehandlungsmittel zum Schutz vor Schäden durch chemische Behandlung und zur Reparatur bereits geschädigter Haare enthaltend als Wirksubstanz Alkylguanidin-Verbindungen
AR018915A1 (es) Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
PE69099A1 (es) Inhibidores de proteasas
AR073418A1 (es) Terapia para cancer. metodo
AR046929A1 (es) Piridopirimidinonas

Legal Events

Date Code Title Description
FB Suspension of granting procedure